Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment save search
Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
Published: 2022-12-09 (Crawled : 14:00) - biospace.com/
AMAM 4 | $28.0 0.0% 1.4M
|
Professional, Scientific, and T...
|
| O: 185.44%
H: 288.03%
C: 288.03%
arx788 treatment breast positive cancer her2- her2 metastatic breast cancer
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea
Published: 2023-11-29 (Crawled : 12:30) - globenewswire.com
VVOS | $2.72 2.26% 2.21% 34K
|
Health Technology
|
| O: 171.75%
H: 308.97%
C: 243.67%
fda device treatment clearance therapeutics
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
Published: 2022-03-21 (Crawled : 13:00) - biospace.com/
NRSN | $1.435 -5.59% -5.92% 120K
|
|
| O: 39.74%
H: 275.23%
C: 185.78%
treatment fda als clearance therapeutics fda clearance primec
Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks
Published: 2022-12-08 (Crawled : 12:00) - globenewswire.com
PHVS | $19.33 4.94% 4.71% 130K
|
|
| O: 66.93%
H: 184.96%
C: 173.51%
phvs416 treatment positive study
NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Fibromyalgia with its Wearable Neurostimulation Technology
Published: 2021-07-20 (Crawled : 16:00) - biospace.com/
NURO | News | $4.28 17.26% 14.72% 250K
|
Health Technology
|
| O: 23.62%
H: 197.77%
C: 149.13%
treatment fda device technology fibromyalgia designation
Therapeutic Solutions International Awarded Landmark Patent for Cancer and COVID-19 Treatment
Published: 2021-12-28 (Crawled : 22:00) - biospace.com/
TSOI | $0.0007 0.0% 33M
|
Manufacturing
|
| O: -1.44%
H: 139.02%
C: 138.54%
covid-19 treatment patent covid cancer
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023
Published: 2023-11-13 (Crawled : 13:30) - globenewswire.com
TENX | $3.62 -1.63% -1.66% 14K
|
Health Technology
|
| O: 100.38%
H: 130.23%
C: 98.34%
tnx-103 fda expected treatment clearance hypertension heart therapeutics
AVEO Oncology Announces U.S. FDA Approval of FOTIVDA® (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma
Published: 2021-03-10 (Crawled : 21:01) - biospace.com/
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: 1.73%
H: 86.98%
C: 85.89%
treatment fda renal fda approval approval cell carcinoma
Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
JSPR | $21.61 -6.89% -7.4% 65K
|
|
| O: 210.62%
H: 153.33%
C: 82.67%
treatment disease trial therapeutics positive
PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Published: 2022-09-28 (Crawled : 11:00) - biospace.com/
PEPG | $10.59 -10.6% -11.85% 120K
|
|
| O: 16.92%
H: 111.18%
C: 79.77%
edo51 treatment trial duchenne positive phase 1
Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia
Published: 2021-11-23 (Crawled : 13:30) - biospace.com/
APVO 4 d | $0.721 -6.36% -6.8% 230K
|
Health Technology
|
| O: 25.38%
H: 132.18%
C: 79.07%
treatment myeloid leukemia phase 1 expansion phase 1b leukemia trial therapeutics apvo436 acute myeloid leukemia phase 2b
gammaCore™ Non-Invasive Vagus Nerve Stimulation(nVNS) Receives Breakthrough Device Designation for Treatment of Posttraumatic Stress Disorder (PTSD)
Published: 2022-01-12 (Crawled : 14:00) - biospace.com/
ECOR | $6.0 6.38% 6.0% 7.4K
|
Health Technology
|
| O: 4.27%
H: 70.91%
C: 53.47%
treatment designation
Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan
Published: 2023-12-15 (Crawled : 11:00) - globenewswire.com
VRCA | $6.96 0.87% 0.72% 130K
|
Health Technology
|
| O: 11.7%
H: 64.76%
C: 45.0%
to-208 molluscum japan positive treatment commercialization trial results
Memorandum of Understanding Signed by Miranda Water Treatment Systems and Rainmaker Worldwide Inc.
Published: 2022-10-05 (Crawled : 15:20) - globenewswire.com
RAKR | $0.0018 40.0% 2.4M
|
|
| O: 12.5%
H: 48.89%
C: 44.44%
water treatment
Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment for Wet AMD
Published: 2022-05-31 (Crawled : 12:20) - globenewswire.com
OTLK P | $8.15 -1.69% -1.72% 270K
|
Health Technology
|
| O: -48.46%
H: 60.24%
C: 43.97%
ons-5010 treatment application license therapeutics submission
Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL™ Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells
Published: 2023-05-18 (Crawled : 16:00) - phiopharma.com
PHIO | $0.631 -1.07% -1.08% 29K
|
Health Technology
|
| O: -6.65%
H: 95.16%
C: 43.87%
treatment pharmaceuticals tumor preclinical study
eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID
Published: 2023-02-21 (Crawled : 15:00) - globenewswire.com
EFTR | $1.645 -7.58% -8.21% 200K
|
|
| O: -42.99%
H: 54.67%
C: 43.67%
treatment covid trial therapeutics positive
Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
Published: 2021-01-27 (Crawled : 01:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 3.07%
H: 58.57%
C: 41.81%
covid positive results treatment phase 1b phase 2b
Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2022-05-11 (Crawled : 13:00) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 11.05%
H: 71.96%
C: 40.74%
rgls8429 treatment fda drug disease kidney application therapeutics
Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
Published: 2022-08-22 (Crawled : 13:20) - biospace.com/
NERV | $2.5 1.2% 11K
|
Health Technology
|
| O: 5.96%
H: 57.75%
C: 39.51%
treatment fda drug schizophrenia application roluperidone negative
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.